Pediatric Hematology Oncology | Specialty

Adavosertib/Irinotecan Shows Early Activity in Pediatric Neuroblastoma

April 12th 2021

Adavosertib plus irinotecan showed early activity in a cohort of pediatric patients with neuroblastoma, thus meeting the protocol-defined efficacy end point of the 1/2 ADVL1312 trial.

Dr. Murphy on the Clinical Implications of Pazopanib Plus SBRT in Pediatric Sarcoma

April 7th 2021

Erin Murphy, MD, discusses the clinical implications of pazopanib plus stereotactic body radiotherapy in pediatric sarcoma.

Dr. Murphy on Future Research Efforts With Pazopanib Plus SBRT in Pediatric Sarcoma

April 6th 2021

Erin Murphy, MD, discusses future research efforts with pazopanib plus stereotactic body radiation therapy in patients with pediatric sarcoma.

Genomic Sequencing Identifies Pediatric Therapy-Related Myeloid Neoplasm Defining Variants Prior to Clinical Presentation

April 5th 2021

Somatic KMT2A rearrangements, RAS/MAPK mutations, RUNX1 and TP53 alterations, and MECOM overexpression were all found to be common oncogenic drivers of pediatric therapy-related myeloid neoplasms, arising predominantly after exposure to cytotoxic therapy and identifiable at least 1 year prior to morphologic evidence of neoplasm.

FDA Approves Daunorubicin/Cytarabine for Pediatric Secondary AML

March 30th 2021

The FDA has approved a revised label for daunorubicin/cytarabine (Vyxeos) to include the treatment of pediatric patients aged 1 year and older with newly diagnosed, therapy-related acute myeloid leukemia (AML) or AML with myelodysplasia-related changes.

Dr. Walters on the Drawbacks of Transfusion Dependence in Pediatric Beta-Thalassemia

March 29th 2021

Mark Walters, MD, discusses the limitations of standard blood transfusions in pediatric patients with transfusion-dependent beta-thalassemia.

Pembrolizumab Approved in Europe for Adult and Pediatric Relapsed/Refractory Classical Hodgkin Lymphoma

March 17th 2021

The European Commission has approved an expanded label for pembrolizumab for use as a single agent in the treatment of select adult and pediatric patients aged 3 years and older who have relapsed/refractory classical Hodgkin lymphoma.

Total Body Irradiation Plus Etoposide Improves Survival in Select Transplant-Eligible Pediatric High-Risk ALL

February 25th 2021

Total body irradiation plus etoposide prior to hematopoietic stem cell transplantation resulted in improved overall survival and a lower risk of relapse in pediatric patients with high-risk acute lymphocytic leukemia compared with chemotherapy conditioning.

Dr. Merchant on Incidence of Craniopharyngioma

February 23rd 2021

Thomas E. Merchant, DO, PhD, discusses the incidence of craniopharyngioma.

Dr. Angiolillo on the Toxicity Profile of Traditional Treatment in Pediatric B-ALL

February 22nd 2021

Anne Angiolillo, MD, discusses the adverse effects that are associated with traditional treatment in pediatric B-cell acute lymphoblastic leukemia.

x